Amanda Emmett

3.5k total citations
65 papers, 2.6k citations indexed

About

Amanda Emmett is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Animal Science and Zoology. According to data from OpenAlex, Amanda Emmett has authored 65 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Physiology, 49 papers in Pulmonary and Respiratory Medicine and 6 papers in Animal Science and Zoology. Recurrent topics in Amanda Emmett's work include Asthma and respiratory diseases (52 papers), Respiratory and Cough-Related Research (27 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (27 papers). Amanda Emmett is often cited by papers focused on Asthma and respiratory diseases (52 papers), Respiratory and Cough-Related Research (27 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (27 papers). Amanda Emmett collaborates with scholars based in United States, Canada and Netherlands. Amanda Emmett's co-authors include Kathleen Rickard, Christopher Kalberg, Katharine Knobil, Steven W. Yancey, Nina L. Church, Glenn Crater, Paul Dorinsky, Fred M. Cox, William W. Busse and Antonio Anzueto and has published in prestigious journals such as New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Amanda Emmett

63 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amanda Emmett United States	29	2.3k	2.3k	171	151	97	65	2.6k
K. Kiviranta Finland	9	1.4k 0.6×	1.3k 0.5×	120 0.7×	177 1.2×	87 0.9×	14	1.7k
Claes-Göran Löfdahl Sweden	14	2.1k 0.9×	2.5k 1.1×	59 0.3×	189 1.3×	161 1.7×	16	2.9k
Colin Reisner United States	22	2.2k 0.9×	2.4k 1.1×	65 0.4×	305 2.0×	97 1.0×	122	3.0k
Mathew Williams New Zealand	17	1.2k 0.5×	1.4k 0.6×	67 0.4×	89 0.6×	77 0.8×	35	1.7k
Gabriele Nicolini Italy	24	1.6k 0.7×	1.7k 0.7×	56 0.3×	120 0.8×	84 0.9×	55	2.0k
Mona Palmqvist Sweden	21	1.6k 0.7×	1.4k 0.6×	73 0.4×	424 2.8×	59 0.6×	35	2.0k
Steven Pascoe United Kingdom	17	2.1k 0.9×	2.5k 1.1×	58 0.3×	42 0.3×	186 1.9×	49	2.7k
L. Adamek United Kingdom	14	1.2k 0.5×	1.3k 0.6×	51 0.3×	155 1.0×	100 1.0×	28	1.8k
M. Perpiñá Spain	24	867 0.4×	1.0k 0.5×	30 0.2×	88 0.6×	40 0.4×	95	1.6k
Manuel Soto‐Quiroz Costa Rica	6	719 0.3×	536 0.2×	47 0.3×	155 1.0×	86 0.9×	7	951

Countries citing papers authored by Amanda Emmett

Since Specialization

Citations

This map shows the geographic impact of Amanda Emmett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda Emmett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda Emmett more than expected).

Fields of papers citing papers by Amanda Emmett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda Emmett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda Emmett. The network helps show where Amanda Emmett may publish in the future.

Co-authorship network of co-authors of Amanda Emmett

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda Emmett. A scholar is included among the top collaborators of Amanda Emmett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda Emmett. Amanda Emmett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brown, Robert S., Michelle A. Collins, Simone I. Strasser, et al.. (2022). Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension. Infectious Diseases and Therapy. 11(2). 913–924. 1 indexed citations

Stempel, David A., Ibrahim Raphiou, Kenneth M. Kral, et al.. (2016). Austri, a Large Randomized Study in Adolescents and Adults with Asthma, Assessing the Safety and Efficacy of Salmeterol in Combination with Fluticasone Propionate Compared to Fluticasone Propionate Alone. Journal of Allergy and Clinical Immunology. 137(2). AB389–AB389. 2 indexed citations

Covelli, Henry D., Bonavuth Pek, Isabelle Schenkenberger, et al.. (2015). Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. International Journal of COPD. 11. 1–1. 21 indexed citations

Hanania, Nicola A., et al.. (2010). Triple Therapy of Fluticasone Propionate/Salmeterol Combination 250/50 mcg and Tiotropium Improves Lung Function Compared to Tiotropium Monotherapy. CHEST Journal. 138(4). 867A–867A. 2 indexed citations

Dransfield, Mark T., William C. Bailey, Glenn Crater, et al.. (2010). Disease severity and symptoms among patients receiving monotherapy for COPD. Primary Care Respiratory Journal. 20(1). 46–53. 48 indexed citations

Bleecker, Eugene R., Harold S. Nelson, Monica Kraft, et al.. (2009). β2-Receptor Polymorphisms in Patients Receiving Salmeterol with or without Fluticasone Propionate. American Journal of Respiratory and Critical Care Medicine. 181(7). 676–687. 81 indexed citations

Anzueto, Antonio, Gary T. Ferguson, Greg Feldman, et al.. (2009). Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes. COPD Journal of Chronic Obstructive Pulmonary Disease. 6(5). 320–329. 135 indexed citations

Weiler, John M., Robert A. Nathan, Ned T. Rupp, et al.. (2005). Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Annals of Allergy Asthma & Immunology. 94(1). 65–72. 45 indexed citations

Knobil, Katharine, Kunal Merchant, Chris Kalberg, Amanda Emmett, & Michael J. Cicale. (2004). A Comparison of Patient Perceived Improvement in Symptoms After Initiating Therapy with Either Advair Diskus (fluticasone propionate/salmeterol) 250/50 or Ipratropium/Albuterol. CHEST Journal. 126(4). 806S–806S. 3 indexed citations

10.

Knobil, Katharine, Chris Kalberg, Kunal Merchant, Amanda Emmett, & Michael J. Cicale. (2004). Maintenance of Bronchodilator Response for Advair Diskus 250/50 (Fluticasone Propionate/Salmeterol) but not Ipratropium/Albuterol in Patients with COPD. CHEST Journal. 126(4). 807S–807S. 4 indexed citations

11.

Juniper, Elizabeth F., Michael Wisniewski, Fred M. Cox, et al.. (2004). Relationship between quality of life and clinical status in asthma: a factor analysis. European Respiratory Journal. 23(2). 287–291. 185 indexed citations

12.

Donohue, James F., Christopher Kalberg, Amanda Emmett, Kunal Merchant, & Katharine Knobil. (2004). A Short-Term Comparison of Fluticasone Propionate/Salmeterol with Ipratropium Bromide/Albuterol for the Treatment of COPD. PubMed. 3(3). 173–181. 39 indexed citations

13.

Nathan, Robert A., et al.. (2002). Effect of fluticasone propionate/salmeterol combination product on activity induced bronchospasm in patients with persistent asthma. Journal of Allergy and Clinical Immunology. 109(1). S236–S236. 4 indexed citations

14.

Calhoun, William J., Harold S. Nelson, Robert A. Nathan, et al.. (2001). Comparison of Fluticasone Propionate–Salmeterol Combination Therapy and Montelukast in Patients Who Are Symptomatic on Short-acting β2-Agonists Alone. American Journal of Respiratory and Critical Care Medicine. 164(5). 759–763. 54 indexed citations

15.

Matz, Jonathan, Amanda Emmett, Kathleen Rickard, & Christopher Kalberg. (2001). Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations. Journal of Allergy and Clinical Immunology. 107(5). 783–789. 95 indexed citations

16.

Condemi, John J., Stanley Goldstein, Christopher Kalberg, et al.. (1999). The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Annals of Allergy Asthma & Immunology. 82(4). 383–389. 126 indexed citations

17.

Nathan, Robert A., Jacob L. Pinnas, Howard J. Schwartz, et al.. (1999). A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma. Annals of Allergy Asthma & Immunology. 82(6). 521–529. 39 indexed citations

18.

Knobil, Katharine, Chris Kalberg, Amanda Emmett, & Kathy Rickard. (1998). Adding salmeterol is more effective than increasing the dose of fluticasone for patients with asthma who are symptomatic on low dose fluticasone. 29. 19–20. 3 indexed citations

19.

Wenzel, Sally E., William R. Lumry, Michael Manning, et al.. (1998). Efficacy, Safety, and Effects on Quality of Life of Salmeterol Versus Albuterol in Patients with Mild to Moderate Persistent Asthma. Annals of Allergy Asthma & Immunology. 80(6). 463–470. 38 indexed citations

20.

Kemp, James P., David Cook, Gary A. Incaudo, et al.. (1998). Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Journal of Allergy and Clinical Immunology. 101(2). 188–195. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact